Several anti-epileptic drugs have established psychiatric roles that demonstrate how the boundary between psychiatry and neurology is more porous than the specialty divisions suggest. The crossover indications mean one drug can address comorbidities across both domains.
- Class
- Anticonvulsants with psychiatric uses
- Mechanism
- Multiple mechanisms across class: sodium channel blockade (lamotrigine, carbamazepine, oxcarbazepine), GABA enhancement (valproate, gabapentinoids), glutamate modulation (lamotrigine, topiramate), calcium channel modulation (gabapentinoids)
- Typical dose
- Drug-specific
- FDA indications
- Mood stabilization, anxiety, neuropathic pain, migraine prophylaxis, alcohol use disorder, treatment-resistant depression augmentation
- Key adverse effects
- Drug-specific. Class effects: dose-dependent cognitive effects, weight changes (varies — topiramate weight loss, valproate weight gain), drug interactions
- Representative agents
- Lamotrigine (bipolar depression), valproate (bipolar mania), carbamazepine/oxcarbazepine (bipolar), gabapentin (anxiety, neuropathic pain, AUD), pregabalin (anxiety, neuropathic pain, fibromyalgia), topiramate (migraine prophylaxis, AUD)
Significant crossover between psychiatry and neurology. Lamotrigine for bipolar depression, gabapentinoids for anxiety with neuropathic pain comorbidity, topiramate for migraine + AUD, valproate for bipolar + seizures + migraine prophylaxis. One drug may serve multiple indications.
Lamotrigine — bipolar depression prophylaxis (psychiatric primary) plus seizure disorders (neurology primary). The mood-stabilizing effect is distinct from the antiepileptic effect, both clinically relevant.
Several antiepileptic drugs cross into psychiatry, where their neuronal-stabilizing mechanisms serve mood, anxiety, and behavioral indications beyond seizure control.
Mechanism note: Antiepileptic drugs cross into psychiatry because neuronal stabilization serves mood, anxiety, craving, and impulsivity — but the evidence varies by indication, and gabapentinoids carry a real misuse potential.
Valproate — bipolar mania, seizure disorders, migraine prophylaxis. Three indications across two specialties from one molecule.
Carbamazepine and oxcarbazepine — bipolar disorder, seizure disorders, trigeminal neuralgia (a chronic pain condition managed in neurology). Cross-specialty utility, though drug interactions and the HLA-B*1502 concern in Asian populations limit modern first-line use.
Gabapentinoids (gabapentin, pregabalin) — voltage-gated calcium channel modulation. Anxiety (often off-label but with evidence in GAD, social anxiety), neuropathic pain, fibromyalgia, restless legs syndrome. The patient with anxiety and neuropathic pain may benefit from a single gabapentinoid for both conditions. Abuse potential — particularly with opioid combinations — has become a real concern in the gabapentin landscape. PDMP screening, careful patient selection, caution in patients with substance use history.
Topiramate — migraine prophylaxis, alcohol use disorder (off-label, moderate evidence), occasional bipolar adjunct. Cognitive side effects ("dopamax" — word-finding difficulty, slowed processing) limit higher doses. Weight loss is often viewed as a benefit, though it's a real metabolic effect.
The pattern: pick the agent for the dominant indication, recognize the crossover, and use the secondary effects clinically. The patient with bipolar I and migraine may do well on valproate; the patient with anxiety and chronic pain on a gabapentinoid; the patient with AUD and migraine on topiramate.
- Cost
- Lamotrigine generic ~$10-30/month. Valproate generic ~$10-30/month. Gabapentin generic ~$5-25/month. Topiramate generic ~$10-30/month. Carbamazepine generic ~$15-50/month.
- Generic status
- All major AEDs used in psychiatry are generic.
- Formulary typical
- Tier 1 generics.
- Access friction
- Off-label uses sometimes require PA documenting primary indication.
Prescriber tip: For crossover uses (gabapentin for anxiety, topiramate for AUD), code primary psychiatric/SUD indication. Document gabapentin abuse potential with opioid co-prescription.